{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T06:53:57Z","timestamp":1771570437345,"version":"3.50.1"},"reference-count":28,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"DOI":"10.2340\/actadv.v105.43419","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T04:48:38Z","timestamp":1750135718000},"page":"adv43419","source":"Crossref","is-referenced-by-count":4,"title":["Four Cases of Prurigo Nodularis Requiring Nemolizumab due to Persistent Pruritus or Lesions after Dupilumab Treatment"],"prefix":"10.2340","volume":"105","author":[{"given":"Yoshihito","family":"Mima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Iozumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"key":"115203","doi-asserted-by":"crossref","unstructured":"Pereira MP, Steinke, S, Zeidler C, Forner C, Riepe C, Augustin M, et al. European Academy of Dermatology and Venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol 2018; 32: 1059-1065.","DOI":"10.1111\/jdv.14570"},{"key":"115204","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.14570","DOI":"10.1111\/jdv.14570"},{"key":"115205","unstructured":"Leis M, Fleming P, Lynde CW. Prurigo nodularis: review and emerging treatments. Skin Therapy Lett 2021; 26: 5\u20138."},{"key":"115206","doi-asserted-by":"crossref","unstructured":"Williams KA, Huang AH, Belzberg M, Kwatra SG. Prurigo nodularis: pathogenesis and management. J Am Acad Dermatol 2020; 83: 1567\u20131575.","DOI":"10.1016\/j.jaad.2020.04.182"},{"key":"115207","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2020.04.182","DOI":"10.1016\/j.jaad.2020.04.182"},{"key":"115208","doi-asserted-by":"crossref","unstructured":"Kwatra SG, St\u00e4nder S, Yosipovitch G, Kim BS, Levit NA, O\u2019Malley JT. Pathophysiology of prurigo nodularis: neuroimmune dysregulation and the role of Type 2 inflammation. J Invest Dermatol 2025; 145: 249\u2013256.","DOI":"10.1016\/j.jid.2024.06.1276"},{"key":"115209","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jid.2024.06.1276","DOI":"10.1016\/j.jid.2024.06.1276"},{"key":"115210","doi-asserted-by":"crossref","unstructured":"Yosipovitch G, Rosen JD, Hashimoto T. Itch: from mechanism to (novel) therapeutic approaches. J Allergy Clin Immunol 2018; 142: 1375\u20131390.","DOI":"10.1016\/j.jaci.2018.09.005"},{"key":"115211","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaci.2018.09.005","DOI":"10.1016\/j.jaci.2018.09.005"},{"key":"115212","doi-asserted-by":"crossref","unstructured":"Haas S, Capellino S, Phan NQ, B\u00f6hm M, Luger TA, Straub RH, et al. Low density of sympathetic nerve fibers relative to substance P-positive nerve fibers in lesional skin of chronic pruritus and prurigo nodularis. J Dermatol Sci 2010; 58: 193\u2013197.","DOI":"10.1016\/j.jdermsci.2010.03.020"},{"key":"115213","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jdermsci.2010.03.020","DOI":"10.1016\/j.jdermsci.2010.03.020"},{"key":"115214","doi-asserted-by":"crossref","unstructured":"Nakajima S, Yonekura S, Nakamizo S, Egawa, G, Kabashima K. Dupilumab as a novel treatment option for prurigo nodularis. J Allergy Clin Immunol 2023; 152: 870\u2013872.","DOI":"10.1016\/j.jaci.2023.08.011"},{"key":"115215","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaci.2023.08.011","DOI":"10.1016\/j.jaci.2023.08.011"},{"key":"115216","doi-asserted-by":"crossref","unstructured":"Yosipovitch G, Mollanazar N, St\u00e4nder S, Kwatra SG, Kim BS, Laws E, et al. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med 2023; 29: 1180\u20131190.","DOI":"10.1038\/s41591-023-02320-9"},{"key":"115217","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/s41591-023-02320-9","DOI":"10.1038\/s41591-023-02320-9"},{"key":"115218","doi-asserted-by":"crossref","unstructured":"Paganini C, Talamonti M, Maffei V, Di Raimondo C, Bianchi L, Galluzzo M. Dupilumab for treatment of prurigo nodularis: real-life effectiveness for up to 84 weeks. J Clin Med 2024; 13: 878.","DOI":"10.3390\/jcm13030878"},{"key":"115219","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/jcm13030878","DOI":"10.3390\/jcm13030878"},{"key":"115220","unstructured":"US Food and Drug Administration. Novel drug approvals for 2024. Available from: https:\/\/www.fda.gov\/drugs\/novel-drug-approvals-fda\/novel-drug-approvals-2024"},{"key":"115221","doi-asserted-by":"crossref","unstructured":"Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, et al. Phase 3 trial of nemolizumab in patients with prurigo nodularis. N Engl J Med 2023; 389: 1579\u20131589.","DOI":"10.1056\/NEJMoa2301333"},{"key":"115222","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa2301333","DOI":"10.1056\/NEJMoa2301333"},{"key":"115223","doi-asserted-by":"crossref","unstructured":"St\u00e4nder S, Yosipovitch G, Lacour JP, Legat FJ, Paul C, Reich A, et al. Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances. J Eur Acad Dermatol Venereol 2022; 36: 1820\u20131825.","DOI":"10.1111\/jdv.18377"},{"key":"115224","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.18377","DOI":"10.1111\/jdv.18377"},{"key":"115225","doi-asserted-by":"crossref","unstructured":"Kwatra SG, Bordeaux ZA, Parthasarathy V, Kollhoff AL, Alajmi A, Pritchard T, et al. Efficacy and safety of abrocitinib in prurigo nodularis and chronic pruritus of unknown origin: a nonrandomized controlled trial. JAMA Dermatol 2024; 160: 717\u2013724.","DOI":"10.1001\/jamadermatol.2024.1464"},{"key":"115226","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2024.1464","DOI":"10.1001\/jamadermatol.2024.1464"},{"key":"115227","doi-asserted-by":"crossref","unstructured":"Kawai R, Ichimasu N, Katagiri K. IL-4 and IL-13 are not involved in IL-31-induced itch-associated scratching behaviour in mice. Exp Dermatol 2024; 33: e15115.","DOI":"10.1111\/exd.15115"},{"key":"115228","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/exd.15115","DOI":"10.1111\/exd.15115"},{"key":"115229","doi-asserted-by":"crossref","unstructured":"Sardana K, Mathachan SR, Muddebihal A, Agrawal D, Ahuja A. Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib: a prospective single-arm investigational study. Indian J Dermatol Venereol Leprol 2025; 17: 1\u20136.","DOI":"10.25259\/IJDVL_1017_2024"},{"key":"115230","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.25259\/IJDVL_1017_2024","DOI":"10.25259\/IJDVL_1017_2024"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/43419\/50460","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/43419\/50460","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T04:48:44Z","timestamp":1750135724000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/43419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":28,"URL":"https:\/\/doi.org\/10.2340\/actadv.v105.43419","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,16]]}}}